Twist Bioscience Corporation (NASDAQ:TWST) is one of the best gene-editing stocks to buy according to hedge funds. On November 4, Steven Etoch, an analyst at Stephens, began coverage of Twist Bioscience Corporation (NASDAQ:TWST). Etoch assigned an Overweight rating on the stock and a $41 price target. The analyst cited Twist’s “differentiated, technology-driven DNA synthesis platform” as a key factor in the decision. The platform serves several markets, including drug discovery, next-generation sequencing ...

Industry Overview - Genetic manipulation, or gene editing, involves altering the genetic material (DNA) of organisms, which gained traction in the 1970s with the creation of recombinant DNA (rDNA) molecules and saw significant commercialization growth with the introduction of the CRISPR-Cas9 system in the 2010s [2][3] - The CRISPR ecosystem currently has 1,031 active companies, with 298 raising approximately $35.8 billion across over 1,200 funding rounds, and the industry is projected to reach a size of $10.8 billion by the end of 2025, expanding at a 16.9% CAGR to nearly $24 billion by 2030 [3] Investment Insights - Hedge funds are showing high interest in gene editing stocks, with notable investments such as BlackRock acquiring over 980,000 additional shares in a leading gene editing company in Q3 2025 [5] - The methodology for identifying the best gene-editing stocks involved reviewing sector exposure through ETF holdings and media coverage, focusing on companies developing and commercializing gene-editing technologies, resulting in a list of nine firms with strong hedge fund support [7] Company Highlights Editas Medicine Inc. (NASDAQ:EDIT) - Editas Medicine is recognized as a top gene-editing stock, with 11 hedge fund holders, and has a price target raised to $4.60 from $4.00 by Clear Street, which noted the company's extended cash runway into Q3 2027 [9][10] - The company reported Q3 2025 results with an EPS of –$0.28 and revenues increasing to $7.5 million from $0.1 million in Q3 2024, driven by collaboration with Bristol Myers Squibb [11] - Editas is focused on developing transformative in vivo therapies using CRISPR technology, with plans to file for IND/CTA by mid-2026 and achieve human proof-of-concept data by year-end 2026 [12] Twist Bioscience Corporation (NASDAQ:TWST) - Twist Bioscience has 23 hedge fund holders and received an Overweight rating with a $41 price target from analyst Steven Etoch, who highlighted its differentiated DNA synthesis platform [13][14] - The company has experienced strong revenue growth of 22.7% over the past year and a five-year CAGR of 42%, with expectations to reach adjusted EBITDA break-even by the end of fiscal year 2026 [14] - Twist's proprietary silicon-based platform enables rapid gene synthesis for applications in drug discovery, diagnostics, and precision medicine, strengthening its market position [16]